Study of Bexarotene in Patients With Acute Myeloid Leukemia

Clinical Trial ID NCT00316030

Rank	Title	Journal	Year	PubWeight™‹?›
1	Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells.	J Med Chem	1995	1.83
2	Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids.	J Med Chem	1994	1.68
3	Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.	J Clin Oncol	2001	1.59
4	Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer.	J Clin Oncol	2003	1.00
5	A Phase I study of LGD1069 in adults with advanced cancer.	Clin Cancer Res	1999	0.94
6	Effects of novel retinoid X receptor-selective ligands on myeloid leukemia differentiation and proliferation in vitro.	Blood	1996	0.89
7	19-nor vitamin-D analogs: a new class of potent inhibitors of proliferation and inducers of differentiation of human myeloid leukemia cell lines.	Blood	1998	0.82
8	Placebo-controlled trial of bexarotene, a retinoid x receptor agonist, as maintenance therapy for patients treated with chemotherapy for advanced non-small-cell lung cancer.	Clin Lung Cancer	2001	0.75